Login to Your Account

Aerie shares climb ahead of glaucoma drug adcom

By Michael Fitzhugh
Staff Writer

Thursday, October 12, 2017

Aerie Pharmaceuticals Inc.'s claims about the efficacy of its triple-acting glaucoma drug, Rhopressa (netarsudil), earned uncomplicated support from FDA briefing docs published ahead of the agency's Friday Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) meeting, sending company shares (NASDAQ:AERI) climbing 16.2 percent to $64.30 on Wednesday as the company took another substantive step toward an anticipated Feb. 28 approval or earlier.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription